Drug Profile
Research programme: TNF alpha release inhibitors - Renovis
Latest Information Update: 25 Apr 2007
Price :
$50
*
At a glance
- Originator Renovis
- Class Small molecules
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Neurological disorders
Most Recent Events
- 25 Apr 2007 Discontinued - Preclinical for Neurological disorders in USA (unspecified route)
- 01 Jun 2004 Preclinical trials in Neurological disorders in USA (unspecified route)